Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
76-22-2
Molecular formula
C10H16O
Molecular weight
152.23 g/mol
Drug class
Topical counterirritantterpene ketone used in external analgesic preparations
Mechanism of action
Produces a local cooling and counterirritant sensation through effects on transient receptor potential (TRP) channels in cutaneous sensory neurons. The perceived cooling and counterirritant response can transiently reduce awareness of superficial pain or itching.
Indications / reported uses
Temporary relief of minor muscle and joint aches when used in topical external analgesic products
Symptomatic relief of minor itching or irritation in selected topical formulations; do not apply to broken skin or use by ingestion
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Camphor Environmental Risk Assessment (ERA) (the Camphor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.